Streptococcal C5a peptidase vaccine

Details Streptococcal C5a peptidase vaccine Streptococcal C5a peptidase vaccine

2004-08-10

2009-12-22

Devi, S. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C424S244100, C424S184100, C424S234100, C424S193100, C424S831000, C514S008100, C514S002600, C514S023000, C530S350000, C530S300000, C530S825000

Reexamination Certificate

active

07635483

ABSTRACT:
Novel vaccines for use against β-hemolyticStreptococcuscolonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolyticStreptococcuscolonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

REFERENCES:
patent: 4152411 (1979-05-01), Schall, Jr.
patent: 4346074 (1982-08-01), Gilmour et al.
patent: 4454121 (1984-06-01), Beachey et al.
patent: 4695562 (1987-09-01), Beachey et al.
patent: 4772584 (1988-09-01), Cleary et al.
patent: 5124153 (1992-06-01), Beachey et al.
patent: 5162226 (1992-11-01), Beachey et al.
patent: 5679654 (1997-10-01), Tzianabos et al.
patent: 5846547 (1998-12-01), Cleary
patent: 6100380 (2000-08-01), Green et al.
patent: 6270775 (2001-08-01), Cleary
patent: 6355255 (2002-03-01), Cleary et al.
patent: 6951653 (2005-10-01), Cleary et al.
patent: 7256265 (2007-08-01), Cleary et al.
patent: 2004/0052801 (2004-03-01), Cleary et al.
patent: 2005/0136068 (2005-06-01), Cleary et al.
patent: 2006/0153879 (2006-07-01), Cleary et al.
patent: WO 89/09063 (1989-10-01), None
patent: WO 89/09064 (1989-10-01), None
patent: WO 93/14198 (1993-07-01), None
patent: WO 93/21220 (1993-10-01), None
patent: WO 94/06421 (1994-03-01), None
patent: WO 94/06465 (1994-03-01), None
patent: WO 95/28960 (1995-11-01), None
patent: WO 97/26008 (1997-07-01), None
Stafslien et al. J. Bacteriol. 182: 3254-3258, 2000.
Cheng et al. Infect. Immun. 70: 6409-6415, 2002.
Feldman et al. J. Immunol. Methods 29: 37-45, Mar. 1994, abstract.
The Concise Encyclopedia: Biochemistry and Molecular Biology. (Ed) Scott et al. Third Edition, Walter de Gruyter, New York, p. 489, (1997).
Alexander et al., “Amino acid changes affecting the activity of pneumolysin alter the behaviour of pneumococci in pneumonia”,Microb Pathog., 24(3), 167-174 (1998).
Anderson et al., “Processing, stability, and kinetic parameters of C5a peptidase fromStreptococcus pyogenes,” Eur. J. Biochem., 269, 4839-4851 (2002).
Cheng et al., “The Group B Streptococcal C5a Peptidase Is Both a Specific Protease and an Invasin,”Infection and Immunity, 70, 2408-2413 (2002).
Feldman et al., “Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo”,Am J Respir Cell Mol Biol., 5(5), 416-423 (1991).
Houghten et al. Vaccines86, Cold Spring Harbor Laboratory, p. 21-25, (1986).
Lazar et al., “Transforming growth factor alpha: Mutation of aspartic acid 47 and leucine 48 results in different biological activities”,Mol Cell Biol., 8(3), 1247-1252 (1988).
Mitchell et al., “Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein”,Mol Microbiol., 5(8), 1883-1888 (1991).
Berg, Andreas, et al., “Streptococcal Cystein Proteinase Releases Biologically Active Fragments of Streptococcal Surface Proteins”,The Journal Of Biological Chemistry, 270(17), (1995),9862-9867.
Bessen, D. , et al., “Influence of Intranasal Immunization with Synthetic Peptides Corresponding to Conserved Epitodes of M Protein on Mucosal Colonization by Group A Streptococci”,Infection and Immunity, 58(10), (1988),2666-2672.
Bessen, D , et al., “Synthetic Peptide Vaccine Against Mucusal Colonization by Group A Streptococci. I. Protection Against a Heterologous M Serotype with Shared C Repeat Region Epitopes”,J Immunol, 145(4), (1990),1251-1258.
Booth, S. , et al., “Dapsone Suppresses Integrin-Mediated Neutrophil Adherence Function”,The Journal of Investigative Dermatology, 98(2), (1992),135-140.
Boyle, M. , et al., “Measurement of Leukocyte Chemotaxis in Vivo”,Methods in Enzymology, 162, (1988),101-114.
Bronze, M. , et al., “Epitopes of group A streptococcal M protein that envoke cross-protective local immune responses”,J. Immunol., 148(3), (1992),868-893.
Bronze, M. , et al., “Protective Immunity Evoked by Locally Administered Group A Streptococcal Vaccines in Mice”,J. Immunol., 141(8), (1988),2767-2770.
Brummer, E. , et al., “Immunological Activation of Polymorphonuclear Neutrophilis for Fungal Killing: Studies with Murine Cells and Blastomyces Dermatitidis In Vitro”Journal of Leukocyte Biology, 36, (1984),505-520.
Carter, Paul ; et al., “Dissecting the catalytic triad of a serine protease”,Nature, vol. 332, XP002135964, (Apr. 7, 1988),564-568.
Chen, Cecil C., et al., “Complete Nucleotide Sequence of the Streptococcal C5A Peptidase Gene ofStreptococcus pyogenes”, The Journal of Bilogical Chemistry, 265(6), (1990),3161-3167.
Clark, J. , et al., “A New Method for Quantitation of Cell-Mediated Immunity in the Mouse”,Journal of the Reticuloendothelial Society, 25(3), (1979),255-267.
Cleary, P. , et al., “A Streptococcal Inactivator of Chemotaxis: A new Virulence Factor Specific to Group A Streptococci”,Recent Advances in Streptococci and Streptococcal Diseases(Y. Kimura, S. Kotami and Y. Shiokawa (ed). Reedbooks ltd; Berkshire, England, (1984),179-180.
Cleary, P. , et al., “Similarity Between the Group B and A Streptococcal C5a Peptidase Genes”.Infection and Immunity, 60(10), (1992),4239-4244.
Cleary, P , et al., “Streptococcal C5a Peptidase is a Highly Specific Endopeptidase”,Infection and Immunity, 60(12),(1992),5219-5223.
Cleary, P., et al., “Virulent Human Strains of Group G Streptococci Express a C5a Peptidase Enzyme Similar to that Produced by Group A Streptococci”,Infection and Immunity, 69(7), (Jul. 1991),2305-2310.
Courtney, H. S., et al., “Analysis of the role of M24 Protein in group A Streptococcal adhesion and colonization by use of ‘omega’-interposon mutagenesis”,Infect. Immun., 62(11), (1994),4868-4873.
Fenderson, P. , et al., “Tropomyosin Shares immunology Epitopes with Group A Streptococcal M Proteins”,The Journal of Immunology, 142(7), (Apr. 1989),2475-2481.
Fischetti, V. A., et al., “Protection against streptoccal pharyngeal colonization with vaccines composed of M protein conserved regions”,Adv. Exp. Med. Bio., 303, (1991),159-167.
Fischetti, V. A., et al., “Protection against streptococcal pharyngeal colinization with a vacine: M protein recombinant”,Science, 244, (1989)1487-1490.
Fischetti, V., “Streptococcal M Protein: Molecular Designn and Biological Behavior”,Clinical Microbiology Reviews, 2(3), (Jul. 1989),285-314.
Hill, H. , et al., “Group B Streptococci Inhibit the Chemotactic Acitvity of the Fifth Component of Complement”,The Journal of Immunology, 141(10), (1988),3551-3556.
Hope-Simpson, R. , “Streptococcus Pyoganes in the Throat: A study in a small population, 1962-1975”,J. Hyg. Camb., 87, 109-129.
Ji, Y. , et al., “C5a peptidase alters clearance and trafficking of group A streptococci by infected mice”,Infection and Immunity, 64(2), (1996).503-510.
Ji, Y , et al., “Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A streptococcus”,Infect. Immun., 65(8), (1997) 2080-2087.
Kapur, V. , et al., “Vaccination with streptococcal extracellular cystaine protease (interleukin-1B convertase) protects mice against challenge with heterologous group A steptococci”,Microbial. Path., 16(6), (1994),443-450.
Laemmli, U. K., “Cleavage of Structural Proteins during the Assembly of the Head . . .”,Nature: International Journal of Science, vol. 227 (1970),680-685.
Lee, P., et al., “Quantification and Toxicity of Group A Streptococcal Pyrogenic Exotoxins in an Animal Model of Toxic Shock Syndrome-Like Illness”,Journal of Clinical Microbiology, 27(8), (1989),1890-1892.
Martin, T. , et al., “The Ef

Affiliated with

Also associated with

Rating

Streptococcal C5a peptidase vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Streptococcal C5a peptidase vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcal C5a peptidase vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4121619